Alzheimer's Drug Shows 92% Safety Rate in Japan Study

Over 90% of Alzheimer's patients in Japan continue treatment with Lecanemab without serious side effects, new research confirms.

The breakthrough drug slows disease progression by targeting brain plaque buildup.